Immunotherapy and evolving approaches for basal cell carcinoma

touchPANEL DISCUSSION for touchONCOLOGY Listen to leading experts discuss evolving treatment options for patients with EGFR-mutant NSCLC, and the rationale for biomarker testing in both early-stage and metastatic disease to determine best treatment approaches, taking in recently presented data from the World Lung Cancer Congress and ESMO Congress 2021. The experts Dr Pasi Jӓnne, Dana-Farber Cancer Institute, Boston, MA, USA Dr Thanyanan Reungwetwattana, Ramathibodi Hospital, Bangkok, Thailand Dr Neal Navani, University College London, London, UK This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent educational grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/deciphering-data-egfr-mutant-nsclc/